Biologically stable alpha-interferon formulations

Details Biologically stable alpha-interferon formulations Biologically stable alpha-interferon formulations

1983-09-16

1985-01-29

Hazel, Blondel

Drug, bio-affecting and body treating compositions

Lymphokine

260112R, 435 68, A61K 4502, C12P 2100

Patent

active

044965370

ABSTRACT:
The addition of glycine or alanine prior to lyophilization significantly improves the biological stability of alpha type interferon formulations.

REFERENCES:
patent: 2553497 (1951-05-01), Orut et al.
patent: 2806815 (1957-09-01), Singher et al.
patent: 3016398 (1962-01-01), Larson et al.
patent: 4198479 (1980-04-01), Tytell et al.
patent: 4289690 (1981-09-01), Pestka et al.
patent: 4337242 (1982-06-01), Markus et al.
Billiau, A., et al., Antimicrobial Agent and Chemotherapy, vol. 16, pp. 49-55, 1979.
Sedmak, J., et al., "Procedures for Stabilisation of Interferon", in Methods in Enzymology, vol. 78, Part A, Academic Press, pp. 591-595, 1981.
Cantell, K., et al., Proc. of Tissue Culture Association Workshop, Lake Placid, N.Y., pp. 35-39, 1973.

Affiliated with

Also associated with

Rating

Biologically stable alpha-interferon formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Biologically stable alpha-interferon formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biologically stable alpha-interferon formulations will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-506070